Quovadx Inc

Quovadx — Merger or Acquisition (April 2007)

11 slides from Quovadx's merger presentation, Apr 2, 2007

  1. Slide 1: Conclusion of Quovadx Strategic Review: The Clearest Path to Value

    Conclusion of Quovadx Strategic Review: The Clearest Path to Value

  2. Slide 2: Safe Harbor Statement

    Certain forward-looking statements are included in this release, including statements relating to a proposed transaction between Quovadx Inc. and Battery Ventures. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-

  3. Slide 3: About Quovadx

    About Quovadx Historical issues presented a number of serious challenges New management team worked to stabilize the Company and position it for growth Focused the business Increased investment in R&D, sales and marketing Launched new products in all three divisions Expanded selling relationships Re

  4. Slide 4: Strategic Review Process

    Strategic Review Process In August 2006, Board initiated review of strategic alternatives with the goal of enhancing stockholder value Engaged First Albany Capital to serve as independent financial advisor and Hogan and Hartson LLP as legal advisors Evaluated broad range of alternatives with careful

  5. Slide 5: Transactions Summary

    Transactions Summary Sale of CareScience to Premier Purchase valued at ~$34.9 million, or 2.3x revenue Net proceeds total $33.8 million in cash Final price subject to final working capital adjustments @ March 31, 2007 Tax liability more than offset by NOLs Transaction closed March 30, 2007 Good stra

  6. Slide 6: Strategic Rationale: Clearest Path to Value

    Strategic Rationale: Clearest Path to Value Attractive valuation 24% premium Transactions insulate QVDX stockholders from risks execution timing market competitive legacy issues/overhang public company costs/distractions Good strategic fit for Quovadx businesses

  7. Slide 7: Premier and CareScience

    Premier and CareScience: Privately held Headquartered in San Diego, CA with offices in Charlotte, NC and Washington, DC Largest healthcare alliance in the US Strong alignment of technology, mission, culture and values This transaction delivers premium value to Quovadx and creates opportunities for C

  8. Slide 8: Battery Ventures, ISD and Rogue Wave

    Battery Ventures, ISD and Rogue Wave Private equity firm with >$2 billion in committed capital >25 years experience with technology, infrastructure and software companies Highly regarded in the industry Quovadx a good fit with other portfolio companies This transaction delivers premium value to Quov

  9. Slide 9: Clear Roadmap to Completion

    Clear Roadmap to Completion Proposed timing of transaction milestones: March 30, 2007 - CareScience transaction closed April 1, 2007 - Battery Ventures definitive agreement approved and signed April - Proxy filed May - Proxy mailed June - Special stockholder meeting End of Q2 - Expected close

  10. Slide 10: Transactions Summary: The Clearest Path to Value

    Transactions Summary: The Clearest Path to Value 24% premium to current share price Protects stockholders from risk Protects businesses Protects customers and employees

  11. Slide 11: Thank You

    Thank You < QUOVADX

Quovadx — Merger or Acquisition (April 2007) on 6ix